GlaxoSmithKline reaches $1.25 billion license agreement with Henlius Pharmaceuticals.

In Monday morning Eastern Time, GlaxoSmithKline's stock price dropped by about 0.9%, after the company announced a $12.5 billion licensing agreement with Hengrui Medicine to jointly develop up to 12 innovative drugs. The deal includes a $500 million upfront payment and up to $12 billion in potential milestone payments. This strategic partnership aims to expand GlaxoSmithKline's research and development pipeline in respiratory, immunology, and oncology fields. Following the news, Hengrui Medicine's stock price surged to a four-year high.